Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report

Autor:	J.-L. Montastruc, F. Huguet, Fabien Despas, G. Tournaire, Emmanuelle Bondon-Guitton
Rok vydání:	2016
Předmět:	medicine.medical_specialty medicine.drug_class Disease 030204 cardiovascular system & hematology Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine Medicine Pharmacology (medical) 030212 general & internal medicine Adverse effect Pharmacology business.industry Ponatinib Imatinib Peripheral Surgery Dasatinib chemistry Nilotinib Cardiology business medicine.drug
Zdroj:	Journal of Clinical Pharmacy and Therapeutics. 41:360-361
ISSN:	0269-4727
Popis:	Summary What is known and objective Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. Case description The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. What is new and conclusion Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c2158fd4dc5243ed9174cde2b9f5930e https://doi.org/10.1111/jcpt.12383 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.